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Precis 27 
Patient compliance with 3 month confirmation testing after Essure hysteroscopic sterilization 28 
was increased with transvaginal ultrasound versus hysterosalpingogram. 29 
30 
31 
Abstract32 
Study Objective: To assess if follow-up confirmation testing 3 months after hysteroscopic 33 
sterilization with the Essure device improved with recommendation for transvaginal ultrasound 34 
(TVUS) versus hysterosalpingogram (HSG). 35 
Design: Retrospective, observational case-controlled cohort study (Canadian Task Force 36 
classification II-2) 37 
Setting: Two physician private practice in Evansville, Indiana 38 
Patients Compliance rates for a TVUS confirmation test on 100 women who underwent 39 
hysteroscopic sterilization compared to a previously published cohort of 1004 women who were 40 
scheduled to undergo HSG confirmation test. 41 
Intervention: Acquisition of 3 month confirmation testing after Essure hysteroscopic sterilization 42 
Measurement and Main Results: All women who underwent Essure hysteroscopic sterilization 43 
with recommendation for TVUS confirmation testing between July 2015 and January 2017 were 44 
compared to a previously published cohort of 1004 patients with recommendation for HSG 45 
confirmation testing (HSG cohort). In addition, an HSG subgroup cohort (HSG subgroup) similar 46 
in size and closest chronology to the TVUS cohort was drawn from the original 1004 patients 47 
and analyzed for HSG follow-up. Records for all patients were reviewed for demographic, 48 
procedural, confirmation testing, and outcome data. One hundred patients were identified with 49 
successful Essure device placement and a recommendation for TVUS confirmation testing. 50 
Eighty-eight (88.0%) patients returned for TVUS at 3 months.  In the HSG cohort, 1004 51 
successful Essure devices were placed and 778 patients returned for the recommended HSG 52 
Page 2 of 17
Downloaded for Anonymous User (n/a) at Indiana University - Ruth Lilly Medical Library from ClinicalKey.com by Elsevier on January 02, 2018.
For personal use only. No other uses without permission. Copyright ©2018. Elsevier Inc. All rights reserved.
3 
 
Jeirath et al.              Hysteroscopic Sterilization Follow-up Rates                                    
 
follow-up (77.5%). There was a significantly higher follow-up rate for TVUS compared to the 53 
HSG cohort (88.0% vs 77.5%, p = 0.008). In the HSG subgroup, 184 patients were identified 54 
and 133 patients presented for HSG follow-up (72.3%) indicating a significantly higher follow-up 55 
rate in the TVUS cohort (88.0% vs 72.3%, p = 0.001). No pregnancies after any confirmation 56 
testing were noted. 57 
Conclusion: Confirmation testing with transvaginal ultrasound rather than hysterosalpingogram 58 
3 months after Essure device placement results in increased patient compliance that may lead 59 
to improved patient outcomes with reduction of unintended pregnancy. 60 
 61 
Keywords: Essure; Hysterosalpingogram; Hysteroscopic sterilization; Transvaginal ultrasound 62 
 63 
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Introduction 66 
Sterilization is the most commonly used form of contraception among women in the United 67 
States (US).1 The only Food and Drug Administration (FDA) approved hysteroscopic method 68 
involves placement of an Essure device to induce fallopian tube occlusion. The Essure micro-69 
insert is a spring-like device that consists of a stainless steel inner coil, a nickel titanium (nitinol) 70 
expanding outer coil, and polyethylene terephthalate (PET) fibers that are wound in and around 71 
the inner coil.2 Benefits to hysteroscopic sterilization are the ability to perform the procedure in 72 
the office setting reducing cost, avoiding intra-abdominal surgery and general anesthesia, and 73 
shorter recovery times.3-5    74 
A disadvantage of Essure is that it requires women to undergo radiologic imaging three months 75 
after the procedure to ensure proper device location and/or tubal occlusion before the procedure 76 
can be relied upon for pregnancy prevention.6 Prior to 2015, the only approved confirmatory test 77 
was a modified hysterosalpingogram (HSG) and follow-up rates are reported to vary between 78 
13% to 92%.6-8 Unfortunately, studies have shown failure to complete confirmation testing 79 
increases risk for unintended pregnancies.9 In July 2015, the FDA approved transvaginal 80 
ultrasound (TVUS) as an alternative method for confirmation in appropriately selected 81 
individuals (Figure 1).10  82 
Although TVUS has been widely utilized in non-US countries with no increase in pregnancy 83 
rates,11,12 TVUS has not been widely adopted in the US and little data exist to detail its use in 84 
this population. In addition, availability of the Essure device has been reduced worldwide 85 
magnifying the need to evaluate the least invasive methods of confirmation testing in the US 86 
population. In October 2015, one private practice in Indiana began recommending TVUS for 87 
confirmation testing. The purpose of this study is to assess whether follow-up confirmation 88 
testing rates at three months after Essure hysteroscopic sterilization improved with 89 
recommendation for TVUS over HSG. 90 
 91 
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Methods 92 
A retrospective, observational case-controlled cohort study was undertaken to evaluate women 93 
who underwent hysteroscopic sterilization with the Essure device with recommendation for 94 
transvaginal ultrasound confirmation testing between July 2015 and January 2017 at a single 95 
private practice in a suburban setting in southern Indiana. All patients scheduled for an Essure 96 
procedure during this time period with either of two physicians at this practice were included in 97 
the study. This time period was selected because TVUS confirmation of Essure was first FDA 98 
approved in July 2015 and prior to July 1, 2015 all patients who had the procedure performed 99 
were recommended to undergo HSG as the sole confirmatory test. Data were collected on 100 
patient age at time of procedure, gravidity, parity, length of procedure, pain during procedure, 101 
number of trailing coils, compliance with recommended confirmatory TVUS or HSG, and any 102 
subsequent procedures performed post-sterilization. 103 
A previously published dataset from the same private practice recording outcomes of Essure 104 
sterilization in 1024 patients was used as the HSG comparison data (HSG cohort).13 The HSG 105 
dataset evaluated all patients who had an attempted Essure procedure between January 2006 106 
and March 2014 with similar data collection utilized for the current study. Compliance rates for 107 
confirmation HSG rather than TVUS were recorded in this dataset as HSG was the only 108 
approved confirmation test for Essure during this time period.  109 
The HSG cohort was collected over a much longer timeframe than the TVUS cohort resulting in 110 
an unbalanced study design. To address the possibility that differences in follow-up or 111 
counseling practices could be related to this, an HSG subgroup was obtained that spanned a 112 
similar time frame as the TVUS cohort. A subgroup of patients undergoing the Essure 113 
procedure in the 81-week period before April 15, 2014 was also analyzed to compare follow-up 114 
rates between HSG and TVUS over a time period of similar duration with minimal separation in 115 
time between collection periods (HSG subgroup).  116 
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The FDA has mandated specific training for practitioners and ultrasonographers to perform 117 
TVUS Essure confirmation testing and is offered through Bayer, Inc. Criteria for TVUS 118 
confirmation testing eligibility after the Essure procedure include: no uterine perforation during 119 
procedure, easily identified bilateral tubal ostia, certainty of bilateral placement with no concern 120 
for tubal perforation such as loss of resistance or use of excessive force during placement, 121 
procedure lasts less than 15 minutes total (scope in, scope out), only 1-8 trailing coils, no 122 
unusual post-operative pain, and patient is not on immunosuppressive therapy.2  123 
The private practice was certified prior to performing any TVUS exam for this study and utilized 124 
a General Electric Voluson P8 3D/4D ultrasound machine. All images were captured with a 125 
transvaginal probe. Ultrasound images were obtained and recorded in accordance with 126 
recommendations and include the following: documentation of uterus orientation in the midline 127 
sagittal view and non-visualization of either insert (scout image); identification of two inserts in 128 
the oblique transverse view with no noted contact between the two devices and noted linear 129 
axis of devices are symmetrical and traversing the interstitial portion of the fallopian tubes; 130 
focused views of bilateral corneal areas with noted linear axis of insert identified as a contiguous 131 
echogenic structure.2 All of the aforementioned images were captured with 2D imaging. All 132 
images are reviewed by physician for meeting criteria for patient to rely. 133 
Greater than 99% of HSG exams were performed in an outpatient radiology facility by board 134 
certified radiologists. A modified low pressure HSG utilizing a 7 French/29cm balloon HSG 135 
catheter was performed on a majority of patients. Radiologists would interpret all images for 136 
device location and tubal occlusion and send reports to the office. The surgeon placing the 137 
Essure devices would review all reports and determine if patients could rely or need further 138 
counseling. 139 
All patients scheduled for either HSG or TVUS 3 month confirmation test were given 140 
appointments for these exams on the day of their procedure. All patients received a phone call 141 
or text from the private practice reminding the patients of the scheduled HSG or TVUS within 1-142 
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3 days prior. If a patient did not present for HSG exam, the practice received a notification from 143 
the radiology department and all patients were attempted to be contacted to reschedule the 144 
exam. If a patient did not present for TVUS, the practice attempted to contact all patients to 145 
reschedule the exam. All patients were informed of coverage for both the Essure procedure and 146 
confirmation test prior to scheduling. 147 
The in-office anesthesia protocol for the Essure procedure evolved over time, with the majority 148 
of patients receiving mild oral sedation, anxiolytic non-sedating doses of intravenous (IV) 149 
fentanyl and/or versed, IV ketorolac, and a paracervical block of either 10 cc of 0.5% 150 
ripovocaine/20cc of 1% lidocaine/30 cc of saline or 20 cc of 1% lidocaine. Pain was recorded on 151 
a scale of 0 to 10 with the patient being instructed that a zero level would indicate no pain and a 152 
level of 10 would represent cramping associated with labor. Pain was recorded immediately 153 
after the procedure was completed and the patient was asked to designate a pain level at the 154 
time of highest pain during the procedure. A 5mm Bettocchi hysteroscopic system was utilized 155 
for all procedures with warmed saline solution as the distention media on pressure up to 100 to 156 
200 mmHg with either speculum assistance or vaginoscopy. 157 
The HSG cohort, HSG subgroup, and TVUS cohort follow-up rates were analyzed with chi-158 
squared tests. Demographic information on the HSG cohort and TVUS cohort was compared 159 
using Wilcoxon–Mann–Whitney and chi-squared tests where appropriate. Post hoc chi-square 160 
tests evaluated the influence of significantly different demographic data on follow-up rates for 161 
the combined HSG full and TVUS cohorts. A p-value of less than 0.05 was considered 162 
significant for all tests. The Institutional Review Board at Indiana University School of Medicine 163 
approved the study as an exempt protocol. 164 
 165 
Results 166 
A total of 109 patients were identified as scheduled for an Essure procedure during the study 167 
period. Of these, 9 patients were excluded from the TVUS follow-up evaluation group. One 168 
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patient had a hysterectomy for abnormal uterine bleeding due to leiomyomata prior to her 3 169 
month follow-up and another had a bilateral salpingectomy before her 3 month follow-up after a 170 
pre-ablation ultrasound revealed a suspected perforated Essure device. Three patients opted 171 
for alternate contraception after failed bilateral Essure placements, and 4 patients were 172 
recommended to undergo HSG due to the number of trailing coils at the time of procedure. Of 173 
the 4 patients advised to undergo HSG testing, all presented for follow-up with 3 patients noted 174 
to have bilateral satisfactory location and one patient to have a right Essure coil noted to be 175 
outside of the tube and abdominally located. 176 
In total, 100 patients were identified as having a successful bilateral or planned unilateral 177 
Essure placement and recommended to undergo TVUS confirmatory testing (Figure 2).  Ninety-178 
eight patients underwent successful bilateral placement and met TVUS criteria. Two patients 179 
were included in the analysis who had intended unilateral Essure placement secondary to 180 
previously known and documented unilateral salpingectomy for ectopic pregnancy. 181 
Of the 100 patients recommended to undergo TVUS confirmatory testing, 88 presented for 182 
appropriate follow-up (88.0%). Twelve patients did not receive a 3-month confirmatory 183 
ultrasound as recommended. However, of those 12 patients, ten had a TVUS prior to a 184 
subsequent in-office ablation within the first 3 months after their Essure. All patients were noted 185 
to have satisfactory location of bilateral Essure devices and patients were informed of these 186 
results. These patients were counseled to return for the scheduled 3-month follow-up Essure 187 
TVUS but did not return. Two patients had Essure placement only but received no follow-up 188 
imaging; One patient was contacted after failing to present for 3 month TVUS and declined to 189 
reschedule and one patient did not return phone calls. All 12 patients were contacted to 190 
reschedule the missed TVUS exam with some patients declining to be rescheduled and others 191 
did not return messages for rescheduling.  192 
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In the HSG cohort, 1004 patients had a successful bilateral Essure device placement and 778 193 
patients returned for the recommended HSG follow-up (77.5%).12 There was a significantly 194 
higher follow-up rate for TVUS compared to HSG (88.0% vs 77.5%, p = 0.008).  195 
In the HSG subgroup that was analyzed over a similar timeframe to the TVUS group, 184 196 
patients were included and 133 patients presented for HSG follow-up (72.3%) indicating a 197 
significantly higher follow-up rate in the TVUS cohort compared to the HSG subgroup (88.0% vs 198 
72.3%, p = 0.001)(Table 1).  199 
No statistically significant difference was observed between patient age, gravidity, parity, or 200 
procedure time between the two groups (Table 2). However, the number of trailing coils and 201 
procedural pain rates were found to be statistically significant between the TVUS and HSG 202 
cohorts. To further evaluate this data, post-hoc chi-square tests were utilized to assess if these 203 
factors influenced follow-up. The number of trailing coils on the left and right were higher in the 204 
TVUS cohort than the HSG cohort (p < 0.001) but this difference did not affect follow-up rates 205 
(coils 0–3: follow-up 78.4%, 4–8: 80.3%, >9: 69.2% and 0–3: 78.3%, 4–8: 78.1%, >9: 77.4%; p = 206 
0.243 and p = 0.496, respectively). Conversely, higher pain ratings were associated with a lower 207 
follow-up rate (pain 0–2: follow-up rate 78.3%, 3–4: 75.0%, 5–6: 82.1%, 7–8: 82.5%, 9–10: 208 
47.6%; p = 0.004). This effect was driven by low follow-up rates for patients that rated pain as 209 
either a 9 or 10. An average pain score of 9-10 in the TVUS cohort was reported over 4.5 times 210 
more frequently than in the HSG cohort (TVUS: 9.18% vs HSG: 1.89%); however, only 2.9% of 211 
the study population was in this category. Despite the negative effect of pain on return rates, 212 
more women obtained a 3 month TVUS compared to HSG. 213 
Being a large referral gynecology only practice, many of the patients at this practice underwent 214 
an Essure device placement as a form of permanent contraception prior to an endometrial 215 
ablation for treatment of heavy menstrual bleeding. In the TVUS cohort, 66 of 100 patients who 216 
underwent a successful Essure procedure had a subsequent endometrial ablation (66.0%). This 217 
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was similar to the HSG cohort where 626 had an ablation after the Essure procedure (62.4%, p 218 
= 0.286). Similar percentages of patients in each group also underwent hysterectomy after 219 
Essure for varying reasons (TVUS 4.0%, HSG 6.3%, p = 0.290). No pregnancies in the TVUS or 220 
HSG cohorts were reported in any patient with successful bilateral or planned unilateral Essure 221 
placement regardless of confirmatory testing method. 222 
 223 
Discussion 224 
In this study, confirmation testing with transvaginal ultrasound versus hysterosalpingogram 3 225 
months after Essure placement resulted in increased patient compliance. Based on previously 226 
reported data, this increased compliance will likely lead to improved patient outcome due to 227 
decrease risk of unplanned pregnancy.9,14 228 
Essure is an effective and well accepted procedure for permanent contraception with a failure 229 
rate at 5–10 years of 0.15%–0.96%.9,14 In a worldwide review of post-Essure pregnancies, 230 
Munro et al. reported that 35% of pregnancies were associated with lack of confirmation 231 
testing.14 Given the clear benefits of confirmation testing in preventing unintended pregnancies 232 
after Essure, approaches that promote follow-up will be beneficial to patients. Some reported 233 
strategies include prescheduling confirmation testing, placing reminder calls, and pre-234 
determining insurance coverage for confirmation testing.7 As demonstrated by this study, an 235 
additional strategy may be the adoption of TVUS as a first line confirmatory test in appropriately 236 
qualified patients. 237 
In this cohort, all patients that were counseled to undergo HSG testing due to disqualifying 238 
factors for a TVUS confirmation test were compliant in obtaining the HSG exam. This was likely 239 
due to more stringent counseling of patients to obtain HSG when they do not qualify for TVUS. 240 
Disqualifying factors include a more difficult procedure, non-optimal coil count during the 241 
procedure, or uncharacteristic pain noted by the patient before or after the procedure.  These 242 
criteria may serve to better identify the most at risk patients for device malplacement and thus 243 
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pregnancy risk can be more extensively counseled with TVUS exclusion criteria and requiring 244 
closer follow-up. 245 
Some physicians have concerns that TVUS confirmatory testing does not demonstrate 246 
occlusion and therefore are reluctant to adopt this method. Interestingly, HSG has a reported 247 
false positive rate for bilateral occlusion as high as 39% and thus, demonstration of occlusion 248 
does not guarantee occluded tubes.15,16 In this study, no pregnancies from Essure device failure 249 
were reported in either the HSG or TVUS cohorts; although the TVUS pregnancy data has a 250 
shorter amount of follow-up as compared to the HSG cohort. Nonetheless, these results are 251 
consistent with other studies documenting no statistically significant differences in Essure failure 252 
rates when utilizing HSG or TVUS.10,17 The one year effectiveness rate of TVUS in a recent FDA 253 
trial was noted to be 0.67% and was consistent with known effectiveness rates in patients 254 
undergoing HSG for confirmation testing.2  255 
In this study, the reported pain between the TVUS and HSG cohorts was statistically significant 256 
and noted to be higher in the TVUS cohort (p<0.0001).  Furthermore, higher pain levels were 257 
noted to be associated with lower follow-up rates. This represented a paradoxical result in that a 258 
greater proportion of patients returned for TVUS despite having a higher pain level during the 259 
procedure over the HSG cohort. There are two likely explanations for the differences in pain 260 
reported during the Essure procedure between the HSG and TVUS cohorts. One is the in-office 261 
anesthesia protocol evolved over time with overall decreasing utilization of IV pain medications 262 
during the procedure. The HSG cohort represented a time frame from 2006-2014 while the 263 
TVUS cohort occurred from 2015 to 2016.  Secondarily, an additional physician performed the 264 
Essure procedure in the TVUS cohort. In the HSG cohort, one physician performed all the 265 
procedures utilizing a lidocaine/neuropin paracervical block and continued use of this block in 266 
the TVUS cohort.  The additional physician included in the TVUS cohort utilized a lidocaine only 267 
block and patients receiving the lidocaine only block typically reported higher pain. Despite the 268 
higher pain score in the TVUS group compared to the HSG group, more women obtained a 3 269 
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month TVUS compared to HSG indicating that the negative effect of pain was small compared 270 
to a larger positive effect of TVUS on patient compliance. 271 
TVUS offers other clinical advantages over the modified HSG. TVUS is a less invasive form of 272 
testing resulting in decreased patient pain and infection with no patient exposure to radiation. 273 
Additionally, TVUS can be performed in the office setting increasing satisfaction for many 274 
patients by providing convenience, cost effectiveness, and anxiety reduction by avoiding a more 275 
invasive procedure in an unfamiliar healthcare setting.  276 
A notable strength of this study is the opportunity to have both cohorts from the same practice 277 
allowing for a strong statistical control. Demographic information between the groups was 278 
comparable with no statistically significant differences. In addition, patients had similar rates of 279 
subsequent procedures following their Essure procedure including ablation and hysterectomy. 280 
There are several limitations to this study. A confounding factor is that some patients in both 281 
cohorts underwent an early TVUS (between 0-89 days post-Essure) prior to a planned 282 
endometrial ablation procedure with noted satisfactory location of Essure devices. Many of 283 
these patients did not return for their scheduled 3 month confirmatory test suggesting these 284 
patients may not have understood the continued need for the 3 month follow-up TVUS or HSG. 285 
Furthermore, a majority of this cohort is privately insured and may not represent outcomes in 286 
other patient populations. Lastly, in this study all patients undergoing TVUS confirmation testing 287 
completed the imaging in the same office where the Essure procedure was performed. It is 288 
uncertain if the follow-up rates would be similar if patients were sent to an outside facility to 289 
obtain the 3 month TVUS. 290 
Due to the recent FDA approval of TVUS confirmation testing, little short-term or long-term data 291 
is available in the US population. Further studies are encouraged to understand the benefits and 292 
risks of this confirmation testing modality. In our study, confirmation testing with transvaginal 293 
ultrasound versus hysterosalpingogram 3 months after Essure device placement results in 294 
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increased patient compliance that may lead to improved patient outcomes with reduction of 295 
unintended pregnancy. 296 
 297 
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Figure 1     Criteria for Transvaginal Ultrasound Confirmation Testing after Essure* 350 
 No uterine perforation 351 
 Easily identified bilateral tubal ostia 352 
 Certain of bilateral placement 353 
 Procedure lasts less than 15 minutes total 354 
 Only 1-8 trailing coils 355 
 No unusual post-operative pain 356 
 Patient is not on immunosuppressive therapy 357 
 358 
*All criteria must be met to offer transvaginal US in lieu of HSG for confirmatory testing. All physicians and 359 
ultrasonographers must be appropriately trained to perform and interpret TVUS with Essure prior to utilizing this 360 
method for confirmation.(5) 361 
 362 
 363 
 364 
 365 
Figure 2      Essure TVUS Cohort Flowchart 366 
 367 
TVUS, Transvaginal Ultrasound; HSG, Hysterosalpingogram 368 
 369 
 370 
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Table 1: Confirmatory Testing Follow-Up     371 
 
Follow-Up 
(#) 
No Follow-Up 
(#) 
Follow-Up Rate 
(%) 
p-value 
compared to 
TVUS 
TVUS 88 12 88.0 - 
HSG cohort 778 226 77.5 0.011 
HSG subgroup 133 51 72.3 0.002 
TVUS, transvaginal ultrasound; HSG, hysterosalpingogram   372 
 373 
 374 
 375 
 376 
Table 2: Demographic and Procedural Variables for TVUS and HSG Cohorts 377 
 
TVUS Cohort HSG Cohort p-value 
Age 38.7 ± 6.4 37.8 ± 6.2 0.2368 
Gravidity 2.0 ± 1.5 1.8 ± 1.2 0.3089 
Parity 1.7 ± 1.1 1.6 ± 1.1 0.4902 
Procedure Time (minutes) 4.9 ± 4.8 4.8 ± 5.0 0.7183 
Patient Reported Pain 3.9 ± 3.0 2.1 ± 2.7 <0.0001 
Trailing Coils on Right 2.7 ± 2.2 1.8 ± 2.1 <0.0001 
Trailing Coils on Left 3.4 ± 3.0 2.0 ± 2.4 <0.0001 
Subsequent Ablation 66.0% 62.4% 0.3798 
Subsequent Hysterectomy 4.1% 6.3% 0.3158 
Data reported as mean ± standard deviations or percentages.  378 
TVUS, transvaginal ultrasound; HSG, hysterosalpingogram 379 
 380 
 381 
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